Kadimastem Ltd
TASE:KDST
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
K
|
Kadimastem Ltd
TASE:KDST
|
IL |
|
Shah Alloys Ltd
NSE:SHAHALLOYS
|
IN |
|
Vault Minerals Ltd
ASX:VAU
|
AU |
|
C
|
Carmell Corp
NASDAQ:CTCX
|
US |
|
S
|
Societe Generale SA
XHAM:SGE
|
FR |
|
W
|
Wharf Holdings Ltd
HKEX:4
|
HK |
|
Summa Defence Oyj
F:5J40
|
FI |
|
Uravi Defence and Technology Ltd
NSE:URAVIDEF
|
IN |
|
LCI Industries
NYSE:LCII
|
US |
|
Photocure ASA
OSE:PHO
|
NO |
|
Enwave Corp
XTSX:ENW
|
CA |
|
S
|
Snail Inc
NASDAQ:SNAL
|
US |
|
E
|
EPIC Acquisition Corp
AEX:EPIC
|
UK |
|
Check Cap Ltd
NASDAQ:CHEK
|
IL |
|
Isoenergy Ltd
XTSX:ISO
|
CA |
|
F
|
FBD Holdings PLC
ISEQ:EG7
|
IE |
Kadimastem Ltd
Kadimastem Ltd. is a clinical-stage bio-pharmaceutical company engaging in the development of industrial regenerative medicine therapies based on differentiated cells derived from Human Embryonic Stem Cells to treat neurology-degenerative diseases. The Company’s technology enables the differentiation of stem cells into insulin secreting beta cells, as well as a range of neural cells (including Oligodendrocytes, Astrocytes). The firm produces islet-like clusters that show glucose-stimulated insulin secretion. In addition, the Company is partnering with pharmaceutical companies interested to screen potential drug compounds (hit-lead, lead optimization) on its stem-cell derived cells, primarily oligodendrocytes and astrocytes.
Kadimastem Ltd. is a clinical-stage bio-pharmaceutical company engaging in the development of industrial regenerative medicine therapies based on differentiated cells derived from Human Embryonic Stem Cells to treat neurology-degenerative diseases. The Company’s technology enables the differentiation of stem cells into insulin secreting beta cells, as well as a range of neural cells (including Oligodendrocytes, Astrocytes). The firm produces islet-like clusters that show glucose-stimulated insulin secretion. In addition, the Company is partnering with pharmaceutical companies interested to screen potential drug compounds (hit-lead, lead optimization) on its stem-cell derived cells, primarily oligodendrocytes and astrocytes.
